Expert Opinion on Investigational Drugs · 1996 · 44 citations · 48 references
PharmacyMicrobiologyPharmacologyAntimicrobial PharmacologyDrug DiscoveryMedical MicrobiologyBioactive Small MoleculesFungal Secondary MetabolitesNatural Product Drug DiscoveryActinomyces InfectionsActivitiesAntibiotic DiscoveryBioactive Fungal MetabolitesSecondary Metabolites
Compounds with completely new chemical structures and/or with novel activity continue to be isolated at high rates from Actinomycetes. Per year, about 200 novel compounds are discovered from this origin. Although a large number of these compounds are still isolated on the basis of traditional antibiotic assays, an increasing proportion of compounds are discovered in high-throughput pharmacological screens. Unfortunately, the biological activities of most of them remain poorly characterised. The selection of novel strains combined with the development of new assays should allow further discoveries of bioactive secondary metabolites from Actinomycetes. This review provides some statistical information on actinomycetesderived natural products described over the period 1990 - 1994. Examples of new targets, new compounds with interesting biological activities and novel chemical structures are given (period 1990 - 1995).
48
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Eric J. Brown, Mark W. Albers, Tae Bum Shin et al. · Nature · 1994 · 2.1K citations
Toru Kino, Hiroshi Hatanaka, MICHISANE HASHIMOTO et al. · The Journal of Antibiotics · 1987 · 1.2K citations · Full text
Medicine, Biochemistry, Pharmacology +10
Rapamycin-Induced Inhibition of the 70-Kilodalton S6 Protein Kinase
Daniel J. Price, Jeffrey Grove, Joseph Avruch et al. · Science · 1992 · 666 citations
K. C. Nicolaou, Wei‐Min Dai, S.‐C. TSAY et al. · Science · 1992 · 329 citations